NO20004818L - Stabile doseringsformer av fluoxetin og dets enantiomere - Google Patents

Stabile doseringsformer av fluoxetin og dets enantiomere

Info

Publication number
NO20004818L
NO20004818L NO20004818A NO20004818A NO20004818L NO 20004818 L NO20004818 L NO 20004818L NO 20004818 A NO20004818 A NO 20004818A NO 20004818 A NO20004818 A NO 20004818A NO 20004818 L NO20004818 L NO 20004818L
Authority
NO
Norway
Prior art keywords
fluoxetine
enantiomers
dosage forms
stable dosage
stable
Prior art date
Application number
NO20004818A
Other languages
English (en)
Other versions
NO20004818D0 (no
Inventor
Martin P Redmon
Hal T Butler
Stephen A Wald
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO20004818D0 publication Critical patent/NO20004818D0/no
Publication of NO20004818L publication Critical patent/NO20004818L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kjemisk og fysikalsk stabile farmasøytiske formuleringer av det potente amidepressive fluoxetin, dets enantiomerer og salter.
NO20004818A 1998-03-27 2000-09-26 Stabile doseringsformer av fluoxetin og dets enantiomere NO20004818L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/049,227 US20030013740A1 (en) 1998-03-27 1998-03-27 Stable dosage forms of fluoxetine and its enantiomers
PCT/US1999/006601 WO1999049857A1 (en) 1998-03-27 1999-03-25 Stable dosage forms of fluoxetine and its enantiomers

Publications (2)

Publication Number Publication Date
NO20004818D0 NO20004818D0 (no) 2000-09-26
NO20004818L true NO20004818L (no) 2000-11-23

Family

ID=21958714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004818A NO20004818L (no) 1998-03-27 2000-09-26 Stabile doseringsformer av fluoxetin og dets enantiomere

Country Status (11)

Country Link
US (1) US20030013740A1 (no)
EP (1) EP1067918A1 (no)
JP (1) JP2002509882A (no)
KR (1) KR20010034703A (no)
CN (1) CN1303280A (no)
AU (1) AU3205399A (no)
BR (1) BR9909118A (no)
CA (1) CA2325858A1 (no)
NO (1) NO20004818L (no)
WO (1) WO1999049857A1 (no)
ZA (1) ZA200005189B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010094471A1 (en) 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013088255A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
MX378004B (es) * 2015-12-02 2025-03-10 Jaime Samuel CHAIT AUERBACH Composición oral veterinaria con gabapentina.
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
CH678920A5 (no) * 1989-11-14 1991-11-29 Gergely Gerhard
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
BR9714509A (pt) * 1996-02-09 2000-03-21 Quadrant Holdings Cambridge Formulações sólidas contendo trealose
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
CA2175939C (en) * 1996-05-07 1999-09-14 Michael Warnett Hetherington Manual capsule filling device
ES2227707T3 (es) * 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet

Also Published As

Publication number Publication date
EP1067918A1 (en) 2001-01-17
KR20010034703A (ko) 2001-04-25
ZA200005189B (en) 2001-05-22
NO20004818D0 (no) 2000-09-26
JP2002509882A (ja) 2002-04-02
WO1999049857A1 (en) 1999-10-07
CA2325858A1 (en) 1999-10-07
US20030013740A1 (en) 2003-01-16
CN1303280A (zh) 2001-07-11
AU3205399A (en) 1999-10-18
BR9909118A (pt) 2001-10-16

Similar Documents

Publication Publication Date Title
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DK1023050T3 (da) Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
DK1787639T3 (da) Stabile farmaceutiske formuleringer til tryksamme dosisinhalatorer
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
DE60032331D1 (de) Exendine zur glucagon suppression
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
MXPA03007712A (es) Sales farmaceuticas.
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
NZ526088A (en) Urea substituted imidazoquinoline ethers
ITRM20020264A0 (it) Articolo assorbente e procedimento per la sua fabbricazione.
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
NO20006138L (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1033990T3 (da) 21-Hydroxy-6,19-oxidoprogesteron (21OH-6OP) dets anvendelse som medikament i behandling af glucocorticoidoverskud
NO20004818D0 (no) Stabile doseringsformer av fluoxetin og dets enantiomere
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
NO20010219D0 (no) Polycykliske tiazolidin-2-yliden aminer, fremgangsmåte for deres fremstilling og deres anvendelse som legemiddel